Company Overview
Roivant Sciences Ltd. operates as a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of medicines and technologies, with its clinical product candidates including IMVT-1402, a fully human monoclonal antibody targeting the neonatal fragment crystallizable recept. The company functions within the Healthcare sector and specifically the Biotechnology industry, positioning itself to navigate the rigorous regulatory and scientific landscapes required for bringing novel therapeutic agents to market. At a significant scale, Roivant Sciences Ltd. maintains a market capitalization of $19.90B while reporting annual revenue of $13.31M and employing 750 individuals across its operations. Despite the substantial market capitalization of $19.90B, the current revenue figure of $13.31M suggests that the company's valuation is driven primarily by pipeline potential and strategic asset value rather than current operational cash generation, indicating a high-risk, high-reward profile typical of clinical-stage biotechnology firms where future commercial success is yet to be realized.
Financial Health
The company reported a revenue of $13.31M and a net income of $-809,240,000, revealing a cost structure where operating expenses significantly outweigh top-line earnings, resulting in a profit margin of 0.0%. The EBITDA stands at $-1,264,381,952, further illustrating the intense capital expenditure required for research and development in the biotechnology sector before any commercial profitability is achieved. Free cash flow is reported at $-334,342,944, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injections or asset monetization. The gross margin is listed at 0.0%, while the operating margin is an extreme -16965.3% and the profit margin is also 0.0%, collectively indicating that the company is not yet profitable and that current revenue does not cover the substantial costs associated with its business model. In terms of liquidity and leverage, the company holds $4.53B in cash against $108.94M in debt, supported by a debt-to-equity ratio of 2.19, which suggests a balance sheet that is heavily weighted toward equity financing rather than debt obligations. The current ratio of 30.66 demonstrates an exceptionally strong position regarding short-term liquidity, meaning the company possesses ample current assets to cover its short-term liabilities many times over. Return on Equity is -19.1% and Return on Assets is -14.5%, metrics that reveal management has not yet generated positive returns on the substantial capital invested in the business, reflecting the inherent losses of a company in the clinical development phase.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -26.95, implying that the market is pricing the stock based on future expectations that do not yet materialize into positive earnings, a common scenario for biotechnology firms awaiting key data readouts. The price-to-book ratio stands at 4.62, indicating that the market values the company at a significant premium over its book value, likely attributing high worth to the intellectual property and pipeline assets that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1494.85 and an EV/EBITDA of -12.80 suggest that traditional valuation multiples are distorted by the lack of profitability, forcing analysts to rely on pipeline-dependent metrics instead. The stock has a 52-week high of $30.33 and a 52-week low of $8.73; without a specific current price provided in the facts, the range itself highlights the extreme volatility experienced by the asset over the past year. The beta of 1.21 indicates that the stock price is 21% more volatile than the broader market, meaning it will likely experience sharper increases during bull markets and deeper declines during bear markets compared to the S&P 500.
Growth & Income
Revenue growth year-over-year is -77.8% while earnings growth is N/A, indicating that the company is contracting in terms of recognized revenue, which is characteristic of a company transitioning between clinical phases or managing specific commercial launches where revenue recognition lags behind R&D spend. Since the earnings growth is N/A and the company is not a dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the firm reinvests all available earnings or capital reserves back into the company to fuel further research and development rather than distributing income to shareholders. The absence of a dividend yield confirms that the company prioritizes capital allocation toward expanding its clinical pipeline and acquiring assets over providing current income to investors. Overall, the growth and income profile is defined by significant revenue contraction and zero income distribution, reflecting the early-stage nature of the business where capital preservation and pipeline advancement take precedence over financial returns.